SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining attention as community members rally around its culture-focused approach and relaxed vibe. Built on Solana, it is promoted with the slogan "Like Bitcoin But Way Higher" and associated with a vision to 'Flip big pharma'. The community emphasizes its creative and positive energy, with some comparing it to a small garden where everyone contributes.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

$PMV is trending as the community rallies around its 'PumpMindVirus' meme, celebrating its organic growth and dedicated community engagement. Despite market fluctuations, the community emphasizes the 'pressure' they apply and invite others to join their 'infectious' fun. Discussions highlight the coin's unique meme culture and the strong belief it will break out from the trenches.

Sibanye Stillwater Ltd. is a multinational mining and metals processing group with a diverse portfolio of operations, projects and investments across five continents. It is one of the global recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. The firm mainly engages in the acquisition and exploration of platinum group materials including palladium, rhodium and producing of gold. It also produces and refines iridium, ruthenium, nickel, chrome, copper and cobalt. The company has diversified its asset portfolio into battery metals mining and processing. Sibanye Stillwater was founded on February 1, 2013 and is headquartered in Weltevreden Park, South Africa.

Sibanye Stillwater Limited - ADR

Sibanye Gold Limited

Sibanye Stillwater ($SBSW) is trending as precious metals, particularly platinum and palladium, gain traction; community members highlight the potential for significant gains as these metals are considered undervalued. Investors are discussing potential catalysts such as increased demand and supply constraints. The stock is viewed as a leveraged play on a potential rebound in PGM prices and some analysts are pointing towards a technical breakout.

Bandwidth, Inc. engages in the provision of cloud communications software services. The firm is also involved in delivering experiences through voice calling, text messaging, and emergency services applications. The company was founded by Henry Kaestner and David A. Morken in July 2000 and is headquartered in Raleigh, NC.

Bandwidth Inc - Ordinary Shares - Class A

Bandwidth Inc

Bandwidth Inc. is trending as discussions revolve around its potential role in the scaling of AI voice technology and recent partnerships, including one with Google. Community members debate whether the company is undervalued, citing its revenue and strategic positioning. Mixed earnings results and sell-side ratings contribute to the ongoing discussion.

Direxion Shares ETF Trust - Direxion Daily META Bull 2X Shares

Direxion Daily META Bull 2X Shares

METU is trending as traders discuss recent price action in Meta and its potential for a rebound. Community members are weighing the attractiveness of METU as a leveraged play on $META, sharing bullish sentiment and discussing options strategies with various expiration dates. Some traders are using METU to magnify gains from Meta's potential recovery, while others are wary of the risks associated with leveraged ETFs.

Digimarc Corp. provides digital watermarking technology services. It develops solutions, licenses intellectual property, and provides development services. The company also connects print, audio, and packaging to brand-defined online content, protects, identifies, and tracks digital files, and confirms content and objects are genuine, unaltered, and from an authorized source. Its products include Digimarc Validate, Digimarc Engage, Digimarc Recycle and Digimarc Retail Experience. The company was founded on January 3, 1995 and is headquartered in Beaverton, OR.

Digimarc Corporation

Digimarc ($DMRC) is trending as chatter revolves around leadership, potential contracts, and the company's overall direction. The community is actively discussing the CEO's performance, potential take-private scenarios, and the implications of a major commercial partner's contract status. Discussions also involve the effectiveness of Digimarc's technology and the need for stronger market presence.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending as investors debate its valuation relative to its crypto holdings and exchange platform, especially compared to competitors like Coinbase. Community members are weighing bullish arguments around potential for growth, positive analyst ratings, and potential short squeeze against concerns of high marketing costs. Recent news about Gemini's expansion into prediction markets and partnerships are also fueling discussion.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as the community discusses its pipeline, particularly VS-7375, and its potential in treating KRAS-driven cancers, comparing it to competitors like Revolution Medicines. Bullish sentiment is fueled by encouraging data, potential for a buyout, and the belief that the stock is undervalued, while some express concerns about management and past dilutions. Discussions also revolve around upcoming catalysts, including earnings and potential NCCN guideline inclusion.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending due to an Airbus recall affecting thousands of A320 jets, which some believe could benefit BA. The community is discussing potential gains for Boeing as a result of Airbus's safety concerns, with some expressing concerns for passenger safety regardless of the manufacturer. Broader discussion includes long-term outlooks and potential price movements for Boeing.

Blockstreet is a multichain launch and growth ecosystem focused on accelerating USD1 stablecoin adoption. Through its dedicated Launchpad, it offers smart contract deployment, cross-chain launch support, USD1 liquidity infrastructure, and ecosystem integration. Backed by strategic partners and LayerZero tech, it provides development resources, grants, and advisory to power DeFi, payments, gaming, and real-world asset use cases.

Blocknet

Blocknet is seeing increased attention as traders discuss its potential connection to USD1 and WLFI, with some suggesting it could be a key blockchain. Community members are weighing in on its volatility, launchpad developments, and whether it represents a buying opportunity or a "rug pull."

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avalo Therapeutics (NASDAQ:AVTX) Posts Quarterly Earnings Results, Misses Estimates By $0.52 EPS

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.</li><li>Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.</li><li>On Stocktwits, sentiment turned ‘extremely bullish’ as message activity surged; users highlighted fresh opportunities and long-term upside.</li></ul>Shares of Avalo Therapeutics gained 0.4% in premarket trading on Wednesday amid upbeat investor sentiment ahead of an Oppenheimer analyst call focused on its lead drug candidate, AVTX-009, for hidradenitis suppurativa.&nbsp;The stock is currently trading at a nearly 18-month high.&nbsp;<h2 class="st-heading-2">Pipeline And Trial Progress</h2>Earlier this month, Avalo said it had dosed the first patient in the LOTUS study. The randomized, double-blind, placebo-controlled trial is testing two dosing regimens of AVTX-009, with top-line results expected in 2026.The study’s primary endpoint is the proportion of patients achieving HiSCR75, a 75% reduction in abscess and nodule count at week 16, while secondary measures include HiSCR50 and HiSCR90 response rates, improvements in skin pain and lesion severity, and safety outcomes.AVTX-009 targets interleukin-1β, a cytokine involved in the inflammatory cascade driving HS and several other autoimmune diseases. The drug’s mechanism builds on clinical validation seen with other IL-1 inhibitors and aims to deliver higher potency and longer durability.<h2 class="st-heading-2">Analyst Views&nbsp;</h2>Avalo has drawn attention from multiple brokerages since restarting its HS program this year.In September, H.C. Wainwright raised its price target on Avalo Therapeutics to $25 from $15 and reiterated a ‘Buy’ rating, saying AbbVie’s latest hidradenitis suppurativa data validated the IL-1 pathway but capped efficacy at 45%–50% HiSCR75.Earlier that month, Oppenheimer recommended investors be buyers of Avalo shares ahead of lutikizumab’s open-label Phase 2 data, forecasting “strong results” and expecting AVTX-009, with multiple advantages over lutikizumab, to deliver “at least as good as, and potentially better, efficacy” when LOTUS trial results&nbsp;are read out in mid-2026. The firm maintained an ‘Outperform’ rating and a $35 price target.Separately, TD Cowen initiated coverage with a ‘Buy’ rating, citing AVTX-009’s Phase 2 study in hidradenitis suppurativa and highlighting the high unmet need in a heterogeneous patient population, estimating over $1 billion sales potential.&nbsp;Cantor Fitzgerald also began coverage with an ‘Overweight’ rating, describing Avalo as a clinical-stage biotech focused on autoimmune diseases and noting that AVTX-009, an IL-1N2 antibody, is expected to have a mid-2026 readout.<h2 class="st-heading-2">Stocktwits Traders See Long-Term Upside</h2>On Stocktwits, retail sentiment for Avalo was ‘extremely bullish’ amid a 20% surge in 24-hour message volume.One user noted that the setup still offered opportunities and encouraged others to stay tuned.<stembedurl>https://stocktwits.com/topstockalerts/message/632967338</stembedurl>Another user suggested that Avalo looked like a strong buy and could deliver twentyfold returns for investors willing to hold long term.<stembedurl>https://stocktwits.com/WallGoodman/message/632883343</stembedurl><a href="https://stocktwits.com/symbol/AVTX">Avalo’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avalo’s stock has more than doubled so far in 2025. (Photo credit: Getty Images)

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.

Equity

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of...

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

12 titoli sanitari in movimento, pre-market del 29/03/2024

Titoli in rialzo
Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd .
Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AVTX News

AVTXAvalo Therapeutics Inc